Brief: Quantum Genomics gets positive opinion of Monitoring Board for study of high blood pressure
06/10/2015 17:05
Oct 6 (Reuters) - Quantum Genomics SA ALQGC.PA :
* Positive opinion of the Monitoring Board for continuation, without change to the protocol
of the Phase IIa clinical study underway for high blood pressure
Source text for Eikon: ID:nACT41599
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study